| 76.69 0.03 (0.04%) | 12-08 14:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 105.73  |
1-year : | 123.5 |
| Resists | First : | 90.52 |
Second : | 105.73 |
| Pivot price | 73.32 |
|||
| Supports | First : | 74.25 |
Second : | 64.19 |
| MAs | MA(5) : | 75.86 |
MA(20) : | 72.53 |
| MA(100) : | 77.22 |
MA(250) : | 0 | |
| MACD | MACD : | -1.1 |
Signal : | -2.2 |
| %K %D | K(14,3) : | 80 |
D(3) : | 74.5 |
| RSI | RSI(14): 52 |
|||
| 52-week | High : | 104.31 | Low : | 31.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TEM ] has closed below upper band by 26.0%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 77.98 - 78.29 | 78.29 - 78.62 |
| Low: | 74.01 - 74.33 | 74.33 - 74.66 |
| Close: | 76.13 - 76.69 | 76.69 - 77.27 |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Mon, 08 Dec 2025
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook - TradingView
Mon, 08 Dec 2025
Tempus AI stock rating reiterated at Hold by TD Cowen, $88 target - Investing.com
Sun, 07 Dec 2025
Hsbc Holdings PLC Cuts Holdings in Tempus AI, Inc. $TEM - MarketBeat
Sat, 06 Dec 2025
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Revenue Growth - Quiver Quantitative
Sat, 06 Dec 2025
Nkcfo LLC Makes New $1.27 Million Investment in Tempus AI, Inc. $TEM - MarketBeat
Sat, 06 Dec 2025
Clear Street LLC Takes $21.73 Million Position in Tempus AI, Inc. $TEM - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 173 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 39.9 (%) |
| Held by Institutions | 51.8 (%) |
| Shares Short | 22,190 (K) |
| Shares Short P.Month | 22,130 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.85 |
| Profit Margin | -18.5 % |
| Operating Margin | -18.1 % |
| Return on Assets (ttm) | -9.1 % |
| Return on Equity (ttm) | -72.7 % |
| Qtrly Rev. Growth | 84.6 % |
| Gross Profit (p.s.) | 3.94 |
| Sales Per Share | 6.42 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -221 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -267.02 |
| PEG Ratio | 0 |
| Price to Book value | 27.07 |
| Price to Sales | 12.05 |
| Price to Cash Flow | -60.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|